Although they've seen growth in the last few years, full implementation of outcome-based contracts faces hurdles like expensive technology, outmoded infrastructure and regulations that get in the way.
BridgeBio, which already owns about 66 percent of Eidos, had initially offered to buy the company in August, but the proposed deal was rejected. Eidos is developing a drug in the competitive ATTR space.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The company sources product candidates from academic and commercial research and then launches subsidiary companies to develop them.